Hans Matter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Matter has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Armin Bauer
Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Höchst, Building G878, 65926 Frankfurt am Main (Germany)
6 shared publicationsKurt Ritter
Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Höchst, Building G878, 65926 Frankfurt am Main (Germany)
6 shared publications- Marc Nazaré
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany
6 shared publications Matthias Urmann
Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Höchst, Building G878, 65926 Frankfurt am Main (Germany)
6 shared publicationsMichael Wagner
Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Höchst, Building G878, 65926 Frankfurt am Main (Germany)
6 shared publicationsVolkmar Wehner
Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Höchst, Building G878, 65926 Frankfurt am Main (Germany)
6 shared publications
Latest Publications
- 1 September 2014
- Published by Elsevier in Toxicology Letters
- Vol. 229, S164
Computational prediction of off-target related safety liabilities of molecules: Cardiotoxicity, hepatotoxicity and reproductive toxicity
- 1 September 2014
- Published by Elsevier in Toxicology Letters
- Vol. 229, S164
Computational prediction of off-target related safety liabilities of molecules: Cardiotoxicity, hepatotoxicity and reproductive toxicity
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (18) , 5352-5365
Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (18) , 5352-5365
Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules
- 21 December 2011
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 51 (4) , 905-911
Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein–Ligand Complexes
- 21 December 2011
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 51 (4) , 905-911
Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein–Ligand Complexes
- 21 December 2011
- Published by Wiley in Angewandte Chemie
- Vol. 124 (4) , 929-935
Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein–Ligand Complexes
- 21 December 2011
- Published by Wiley in Angewandte Chemie
- Vol. 124 (4) , 929-935
Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein–Ligand Complexes
- 30 March 2009
- Published by Wiley in Angewandte Chemie
- Vol. 121 (16) , 2955-2960
Evidence for C-Cl/C-Br⋅⋅⋅π Interactions as an Important Contribution to Protein–Ligand Binding Affinity
Attraktives Chlor: Nichtkovalente Wechselwirkungen zwischen Chlor‐ oder Brom‐Atomen und aromatischen Ringen in Proteinen bieten einen neuen Ansatzpunkt für die Beeinflussung der molekularen Erkennung. Die Einführung dieser Substituenten an spezifischen Positionen zweier Faktor‐Xa‐Inhibitoren erhöht deren freie Bindungsenergie durch die Wechselwirkung mit einer Tyrosineinheit. Das allgemeine Vorkommen dieses Strukturmotivs wird anhand zahlreicher Kristallstukturen und quantenchemischer Rechnungen belegt (siehe Bild). magnified image
- 30 March 2009
- Published by Wiley in Angewandte Chemie
- Vol. 121 (16) , 2955-2960
Evidence for C-Cl/C-Br⋅⋅⋅π Interactions as an Important Contribution to Protein–Ligand Binding Affinity
Attraktives Chlor: Nichtkovalente Wechselwirkungen zwischen Chlor‐ oder Brom‐Atomen und aromatischen Ringen in Proteinen bieten einen neuen Ansatzpunkt für die Beeinflussung der molekularen Erkennung. Die Einführung dieser Substituenten an spezifischen Positionen zweier Faktor‐Xa‐Inhibitoren erhöht deren freie Bindungsenergie durch die Wechselwirkung mit einer Tyrosineinheit. Das allgemeine Vorkommen dieses Strukturmotivs wird anhand zahlreicher Kristallstukturen und quantenchemischer Rechnungen belegt (siehe Bild). magnified image
- 30 March 2009
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 48 (16) , 2911-2916
Evidence for C-Cl/C-Br⋅⋅⋅π Interactions as an Important Contribution to Protein–Ligand Binding Affinity
Attractive chlorine: Noncovalent interactions between chlorine or bromine atoms and aromatic rings in proteins open up a new method for the manipulation of molecular recognition. Substitution at distinct positions of two factor Xa inhibitors improves the free energy of binding by interaction with a tyrosine unit. The generality of this motif was underscored by multiple crystal structures as well as high‐level quantum chemical calculations (see picture). magnified image
- 30 March 2009
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 48 (16) , 2911-2916
Evidence for C-Cl/C-Br⋅⋅⋅π Interactions as an Important Contribution to Protein–Ligand Binding Affinity
Attractive chlorine: Noncovalent interactions between chlorine or bromine atoms and aromatic rings in proteins open up a new method for the manipulation of molecular recognition. Substitution at distinct positions of two factor Xa inhibitors improves the free energy of binding by interaction with a tyrosine unit. The generality of this motif was underscored by multiple crystal structures as well as high‐level quantum chemical calculations (see picture). magnified image
- 11 May 2007
- Published by Wiley in QSAR & Combinatorial Science
- Vol. 26 (5) , 618-628
A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors
Cytochrome P450 2C9 (CYP2C9) is one of the most important phase 1 metabolizing enzymes in humans for therapeutically relevant pharmaceuticals. Any new compound inhibiting this membrane‐associated protein would notably affect the metabolism of physiologically important molecules and drugs, resulting in clinically significant drug‐drug interactions. In search for computational tools to identify potential CYP2C9 inhibitors early in discovery, we present here the construction of filters based on 1100 structurally diverse molecules tested for CYP2C9 inhibition under identical conditions. Their chemical structures were encoded using various 2D descriptors including Three‐Point Pharmacophoric (3PP) fingerprints, followed by generation of statistical models using Support Vector Machines (SVM) and Partial Least Squares (PLS). This consistently led to significant and predictive models for regression and classification of CYP2C9 inhibitors. Their predictive ability was underscored by successfully applying them to different test sets of 238 diverse and 344 GPCR‐targeted compounds. Even more important for early drug discovery is the ability of these models to correctly discriminate CYP2C9 inhibitors from inactive molecules. These models collectively are able to identify true CYP2C9 inhibitors with relatively low rates of false positives. The 3PP‐based filter also allows visualizing important substructures and functional groups, which are linked to protein‐ligand interactions for CYP2C9, as illustrated for selected structure‐activity series. The application of these models to the substrate S‐warfarin, recently co‐crystallized with CYP2C9, revealed that the important substructures are indeed involved in the interaction with the CYP2C9 binding site. For example, the model correctly indicated aromatic stacking interactions with Phe114 and Phe476 as well as a hydrogen bond with Phe100. Hence, these models consistently provide guidelines for reducing CYP2C9 inhibition in novel candidate molecules.
- 11 May 2007
- Published by Wiley in QSAR & Combinatorial Science
- Vol. 26 (5) , 618-628
A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors
Cytochrome P450 2C9 (CYP2C9) is one of the most important phase 1 metabolizing enzymes in humans for therapeutically relevant pharmaceuticals. Any new compound inhibiting this membrane‐associated protein would notably affect the metabolism of physiologically important molecules and drugs, resulting in clinically significant drug‐drug interactions. In search for computational tools to identify potential CYP2C9 inhibitors early in discovery, we present here the construction of filters based on 1100 structurally diverse molecules tested for CYP2C9 inhibition under identical conditions. Their chemical structures were encoded using various 2D descriptors including Three‐Point Pharmacophoric (3PP) fingerprints, followed by generation of statistical models using Support Vector Machines (SVM) and Partial Least Squares (PLS). This consistently led to significant and predictive models for regression and classification of CYP2C9 inhibitors. Their predictive ability was underscored by successfully applying them to different test sets of 238 diverse and 344 GPCR‐targeted compounds. Even more important for early drug discovery is the ability of these models to correctly discriminate CYP2C9 inhibitors from inactive molecules. These models collectively are able to identify true CYP2C9 inhibitors with relatively low rates of false positives. The 3PP‐based filter also allows visualizing important substructures and functional groups, which are linked to protein‐ligand interactions for CYP2C9, as illustrated for selected structure‐activity series. The application of these models to the substrate S‐warfarin, recently co‐crystallized with CYP2C9, revealed that the important substructures are indeed involved in the interaction with the CYP2C9 binding site. For example, the model correctly indicated aromatic stacking interactions with Phe114 and Phe476 as well as a hydrogen bond with Phe100. Hence, these models consistently provide guidelines for reducing CYP2C9 inhibition in novel candidate molecules.